Ranbaxy Gets Tentative FDA Approval

Ranbaxy Laboratories has received tentative approval to manufacture and market lamivudine in a 150-mg tablet.

Lamivudine is the generic equivalent of GlaxoSmithKline's (GSK) HIV drug Epivir. Epivir generated roughly $250 million in revenues in the U.S. last year, according to GSK.